MPG.eBooks - Search Results

1

Effectiveness of factor V leiden and prothrombin mutation testing in patients presenting with a first unprovoked venous thromboembolic episode : a systematic review and economic an...

Published 2015

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Prothrombin / genetics...”

Read Now

2

Effectiveness of factor V leiden and prothrombin mutation testing in patients presenting with a first unprovoked venous thromboembolic episode : a systematic review and economic an...

Published 2015

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Prothrombin / genetics...”

Read Now

3

DNA mismatch repair deficiency tumour testing for patients with colorectal cancer: Recommendations

by Assasi, Nazila
Published 2016

CADTH

Subjects: “...DNA Mismatch Repair / genetics...”

Read Now

4

DNA mismatch repair deficiency tumour testing for patients with colorectal cancer: Recommendations

by Assasi, Nazila
Published 2016

CADTH

Subjects: “...DNA Mismatch Repair / genetics...”

Read Now

5

Guidance on the use of factor V leiden and prothrombin mutation testing in patients with a first unprovoked thromboembolic episode

Published 2015

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Prothrombin / genetics...”

Read Now

6

Anaplastic lymphoma kinase inhibitors for genetically rearranged non-small cell lung cancer : a review of cost-effectiveness and guidelines

by Islam, Saadul, Argáez, Charlene
Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Carcinoma, Non-Small-Cell Lung / genetics...”

Read Now

7

Anaplastic lymphoma kinase inhibitors for genetically rearranged non-small cell lung cancer : a review of cost-effectiveness and guidelines

by Islam, Saadul, Argáez, Charlene
Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Carcinoma, Non-Small-Cell Lung / genetics...”

Read Now

8

Anaplastic lymphoma kinase inhibitors for genetically rearranged non-small cell lung cancer : a review of the clinical effectiveness

by Islam, Saadul, Argáez, Charlene
Published 2018

Canadian Agency for Drugs and Technologies in Health

Read Now

9

Drugs for chronic hepatitis C infection : clinical review

by Wells, George A.
Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Hepatitis C, Chronic / genetics...”

Read Now

10

Non-invasive fetal RHD genotyping : a rapid qualitative review

by Herington, Elijah, Loshak, Hannah
Published 2019

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Rh-Hr Blood-Group System / genetics...”

Read Now

11

Non-invasive fetal RHD genotyping : a rapid qualitative review

by Herington, Elijah, Loshak, Hannah
Published 2019

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Rh-Hr Blood-Group System / genetics...”

Read Now

12

Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative : a review of clinical effectiveness and guidelines

Published 2014

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Breast Neoplasms / genetics...”

Read Now

13

Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative : a review of clinical effectiveness and guidelines

Published 2014

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Breast Neoplasms / genetics...”

Read Now

14

Hepatitis C polymorphism testing : a review of the clinical evidence

Published 2014

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Polymorphism, Genetic / drug effects...”

Read Now

15

Hepatitis C polymorphism testing : a review of the clinical evidence

Published 2014

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Polymorphism, Genetic / drug effects...”

Read Now

16

CADTH drug reimbursement recommendation: von Willebrand factor (Recombinant) (Vonvendi -- Takeda Canada Inc.) : indication: treatment and control of bleeding episodes in adults (ag...

Published 2021

Canadian Agency for Drugs and Technologies in Health

“... IU/dL), Type 2B (diagnosed by genotype), Type 2N (FVIII:C < 10% and historically documented genetics...”

Read Now

17

Frenectomy for the correction of ankyloglossia : a review of clinical effectiveness and guidelines

Published 2016

Canadian Agency for Drugs and Technologies in Health

Read Now

18

Frenectomy for the correction of ankyloglossia : a review of clinical effectiveness and guidelines

Published 2016

Canadian Agency for Drugs and Technologies in Health

Read Now

19

CADTH Canadian drug expert committee recommendation: Inotersen (Tegsedi -- Akcea Therapeutics, Inc.) : indication : treatment of polyneuropathy in adults with hereditary transthyre...

Published 2019

Canadian Agency for Drugs and Technologies in Health

“... for reimbursement, initiation criteria 1. Confirmed genetic diagnosis of hATTR. 2. Patients who have all...”

Read Now

20

CADTH Canadian drug expert committee recommendation: Inotersen (Tegsedi -- Akcea Therapeutics, Inc.) : indication : treatment of polyneuropathy in adults with hereditary transthyre...

Published 2019

Canadian Agency for Drugs and Technologies in Health

“... for reimbursement, initiation criteria 1. Confirmed genetic diagnosis of hATTR. 2. Patients who have all...”

Narrow Search